Monitor FDA's decision on INO-3107's accelerated approval pathway by the October 30, 2026 PDUFA date, as this will be a critical catalyst. The stock is likely to remain under pressure due to the company's cash constraints and dilutive capital raising, with any positive FDA developments potentially providing temporary relief.
INO drugs
INO drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 2 $1.13entry
- T+1 · 8mo ago 0.00%α −0.48% · $1.13
- T+5 · 7mo ago −6.19%α −9.81% · $1.06
- T+20 · 7mo ago −0.89%α −10.76% · $1.12
- T+60 · 5mo ago −2.65%α −16.81% · $1.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Inovio Pharmaceuticals is conducting a public offering of common stock and accompanying warrants to raise capital, primarily to prepare for a potential commercial launch of its lead candidate INO-3107 for recurrent respiratory papillomatosis. The offering includes immediate dilution for new investors and comes amid significant uncertainty about FDA approval under the accelerated pathway, with the company acknowledging substantial doubt about its ability to continue as a going concern.
Key Facts
- Company is raising capital through a public offering of common stock and warrants
- Proceeds will be used for commercial launch preparation of INO-3107, confirmatory trial, and pipeline development
- FDA has accepted BLA for INO-3107 under accelerated approval but questioned eligibility, creating significant regulatory uncertainty
- Company acknowledges substantial doubt about its ability to continue as a going concern
- New investors will experience immediate dilution as offering price exceeds net tangible book value
- No established trading market for the warrants being offered
Financial Impact
The offering will provide capital to fund operations, but exact amount undisclosed. New investors face immediate dilution as offering price exceeds net tangible book value per share of $0.35
Risk Factors
- FDA may deny accelerated approval for INO-3107
- Company may not have sufficient capital to fund operations
- Significant dilution for new investors in the offering
- Competition from approved therapy PAPZIMEOS
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-138636 |
| Document: 0001193125-26-138636-index-headers.html | 0001193125-26-138636 |
| Document: 0001193125-26-138636-index.html | 0001193125-26-138636 |
| Document: 0001193125-26-138636.txt | 0001193125-26-138636 |
Track record
20 reports on INO
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 8 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
- Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers